First-Line Intravenous Immune Globulin Monotherapy Evaluated in Idiopathic Inflammatory Myopathy
The investigators concluded first-line IVIG monotherapy led to clinically relevant improvement in nearly one-half of IIM patients, the majority of whom experienced a rapid clinical response.
Decentralized Clinical Trials: Coming Virtually to a Research Facility Near You
Virtual clinical trials may increasingly replace in-person trials due to their advantages in helping to bring drugs to market.
Subcutaneous Immune Globulin May Be a Treatment Option in Stiff Person Syndrome Patients Intolerant to Intravenous Immune Globulin
SCIG may be a reasonable and safe alternative for SPS patients who do not tolerate IVIG, with the caveat that allergic and injection site reactions can be a limiting factor for some patients.
Low Rate of Inhibitor Development in Previously Untreated Hemophilia A Patients Managed with Simoctocog Alfa (Nuwiq)
The investigators concluded PUPs treated with simoctocog alfa had a lower high-titer inhibitor rate than PUPs initially treated with hamster-cell-derived recombinant FVIII products.
Against the Storm: High-Dose IVIG as an Immunoregulatory Treatment Strategy for Severe COVID-19
While there may be no “magic bullet” to treat cytokine storm, one widely used immunomodulatory agent in particular — polyclonal intravenous immune globulin (IVIG) purified from healthy donor plasma — is distinguished by the simple fact that it is anything but a narrowly targeted treatment.
New Vaccines in Development
Beyond COVID-19 vaccines, research is showing potential for new vaccines to treat several other diseases.
Emerging Novel Viruses
With trillions of viruses living in the human and other species’ microbiomes, the possibility of novel viruses such as COVID-19 emerging is high, but the threat they may pose is unknown.
Plasma Exchange May Slow Alzheimer’s Disease Cognitive and Functional Decline: Phase 2b/3 Clinical Study Findings
This trial suggests that plasma exchange with albumin replacement could slow cognitive and functional decline in Alzheimer’s disease, although further studies are warranted.
Lower, More Frequent Dosing of IVIG-Dependent CIDP Patients Does Not Improve Efficacy or Safety in CIDP
The investigators concluded lower, more frequent dosing does not further improve the efficacy of IVIG in stable IVIG-dependent CIDP patients, or result in fewer side effects.
Low Serum Albumin Level Strongly Associated with Severe COVID-19
University of Toledo investigators conducted a systematic review and meta-analysis to determine whether there may be an association between hypoalbuminemia and severe COVID-19.
